HomeONC • TSE
add
Oncolytics Biotech Inc
Previous close
$1.55
Day range
$1.50 - $1.60
Year range
$1.20 - $4.49
Market cap
113.88M CAD
Avg Volume
59.30K
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(CAD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 8.73M | 29.58% |
Net income | -6.89M | -7.10% |
Net profit margin | — | — |
Earnings per share | -0.09 | 13.21% |
EBITDA | -8.70M | -29.57% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(CAD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 29.60M | -0.23% |
Total assets | 34.75M | -1.64% |
Total liabilities | 11.78M | 23.01% |
Total equity | 22.97M | — |
Shares outstanding | 75.42M | — |
Price to book | 5.17 | — |
Return on assets | -59.30% | — |
Return on capital | -83.77% | — |
Cash Flow
Net change in cash
(CAD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -6.89M | -7.10% |
Cash from operations | -7.47M | 4.60% |
Cash from investing | -46.00K | -100.69% |
Cash from financing | 1.50M | -71.64% |
Net change in cash | -5.31M | -226.22% |
Free cash flow | -6.07M | 3.48% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
29